The peptide hormone relaxin is a known modulator of connective tissue and the extracellular matrix (ECM) by virtue of its ability to regulate matrix metalloproteinases (MMPs). Relaxin knock-out mice exhibit age-related pulmonary fibrosis and delivery of recombinant human H2 relaxin ameliorates fibrotic-like conditions in the mouse lung. We investigated whether lentiviral vectors (LVs) engineering the expression of murine relaxins could induce MMP activity in the mouse lung. Mouse relaxin and mouse relaxin-3 peptides engineered by recombinant LVs were biologically active as shown by stimulation of cAMP from both THP-1 and 293T cells stably expressing relaxin receptor LGR7, and by up-regulation of MMP-2 activity from primary C57BL/6 lung cell cultures. To provide the virions with enhanced tropism for the lung, LVs were pseudotyped with the Zaire strain of the Ebola virus glycoprotein (EboZ GP) and delivered by endotracheal intubation. LVs engineering luciferase pseudotyped with EboZ GP, but not with vesicular stomatitis virus glycoprotein (VSVg) resulted in successful LV transduction and transgene expression in C57BL/6 mouse lung by as early as day 4. Mice treated via tracheal delivery with EboZ GP pseudotyped-LVs that engineered expression of mouse relaxins exhibited increased MMP-2 and MMP-9 activity in lung tissue up until the end of our study at day 21. Taken together, this study provides proof-of-principle that relaxin gene expression targeted to the mouse lungs can result in enhanced MMP activity offering potential for alleviating disease conditions characterized by dysregulation of ECM protein accumulation.